4.25
0.13 (3.03%)
| Previous Close | 4.12 |
| Open | 4.10 |
| Volume | 33,596 |
| Avg. Volume (3M) | 332,119 |
| Market Cap | 254,193,632 |
| Price / Sales | 6.55 |
| Price / Book | 5.79 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Operating Margin (TTM) | -2,179.84% |
| Diluted EPS (TTM) | -1.77 |
| Quarterly Revenue Growth (YOY) | 40.00% |
| Total Debt/Equity (MRQ) | 97.55% |
| Current Ratio (MRQ) | 3.35 |
| Operating Cash Flow (TTM) | -54.06 M |
| Levered Free Cash Flow (TTM) | -28.16 M |
| Return on Assets (TTM) | -60.70% |
| Return on Equity (TTM) | -179.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Orchestra BioMed Holdings, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.33 |
|
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 21.81% |
| % Held by Institutions | 49.62% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |